Validation and limitation of CLIP scoring system in 722 Japanese patients with hepatocellular carcinoma and a proposal of better prognostic staging system. Japan integrated staging score (JIS score)
Masatoshi Kudo(Kindai University), Yukio Osaki(Osaka Red Cross Hospital), Yasunori Minami, Hobyung Chung, Masayuki Kitano(Wakayama Medical University), Nobuhiro Fukuda, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Yoichiro Suetomi, Ryosuke Nakaoka, Mikio Shiomi, Toshihiko Kawasaki(Kindai University), Shigenaga Matsui, Chikara Ogawa
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k